Skip to main content

Nephrology Articles tagged as SHSC

Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis

Christopher J. Cooper, M.D., Timothy P. Murphy, M.D., Donald E. Cutlip, M.D., Kenneth Jamerson, M.D., William Henrich, M.D., Diane M. Reid, M.D., David J. Cohen, M.D., Alan H. Matsumoto, M.D., Michael Steffes, M.D., Michael R. Jaff, D.O., Martin R. Prince
N Engl J Med. 2014 Jan 2;370(1):13-22. doi: 10.1056/NEJMoa1310753. Epub 2013 Nov 18

Kidney development: core curriculum 2011

Walker KA, Bertram JF
Am J Kidney Dis. 2011 Jun;57(6):948-58. doi: 10.1053/j.ajkd.2011.03.009. Epub 2011 Apr 22

Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial

Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH; Dutch Working Party on Systemic Lupus Erythematosus
Kidney Int. 2006 Aug;70(4):732-42. Epub 2006 Jul 5

Comparison of two fluid-management strategies in acute lung injury

National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network1, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL
N Engl J Med. 2006 Jun 15;354(24):2564-75. Epub 2006 May 21

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB
N Engl J Med. 2005 Nov 24;353(21):2219-28

Sequential therapies for proliferative lupus nephritis

Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D
N Engl J Med. 2004 Mar 4;350(10):971-80

The classification of glomerulonephritis in systemic lupus erythematosus revisited

Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M
J Am Soc Nephrol. 2004 Feb;15(2):241-50

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C; European Vasculitis Study Group
N Engl J Med. 2003 Jul 3;349(1):36-44

Effect of dialysis dose and membrane flux in maintenance hemodialysis

Eknoyan G1, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group
N Engl J Med. 2002 Dec 19;347(25):2010-9

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Edmund J. Lewis, M.D., Lawrence G. Hunsicker, M.D., William R. Clarke, Ph.D., Tomas Berl, M.D., Marc A. Pohl, M.D., Julia B. Lewis, M.D., Eberhard Ritz, M.D., Robert C. Atkins, M.D., Richard Rohde, B.S., and Itamar Raz, M.D., for the Collaborative Study G
N Engl J Med. 2001 Sep 20;345(12):851-60

Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G
N Engl J Med. 2000 Jan 20;342(3):145-53
[12  >>  
ukidneyisup